FDA Shows Greater Regulatory Flexibility for First-in-Class Drugs Compared to EMA, Study Reveals
核心洞察
A comprehensive analysis of 186 first-in-class drugs (搜索) reveals the FDA granted expedited review to 81% of these innovative therapies between 2013-2023, compared to just 30% at the EMA.
Researchers found concerning trends in clinical trial design, with 50% of pivotal trials lacking clinical endpoints and 30% missing proper blinding or comparator drugs, raising questions about evidence quality.
Cancer (搜索) drugs represented 27% of first-in-class approvals, with 90% of oncology therapies approved based on surrogate endpoints rather than definitive clinical outcomes.
A new study published in Health Affairs reveals significant differences in how first-in-class drugs (搜索) are regulated in the United States compared to Europe, with the US Food and Drug Administration (FDA) demonstrating substantially greater regulatory flexibility than its European counterpart.
Researchers from Brigham and Women's Hospital and Harvard Medical School examined 186 first-in-class drugs (搜索) approved by the FDA between 2013 and 2023, comparing 121 of these that were also approved by the European Medicines Agency (搜索) (EMA) during a similar timeframe.
FDA's Expedited Pathways Dominate First-in-Class Approvals
The analysis revealed that 81% of first-in-class drugs (搜索) received approval under at least one of the FDA's expedited programs—including priority review, accelerated approval (搜索), fast track, and breakthrough therapy designations. In stark contrast, only 30% of these innovative therapies received similar expedited treatment from the EMA.
"From a regulatory and policy standpoint, studying first-in-class drugs (搜索) allows us to assess the extent of regulatory flexibility granted to products considered highly innovative despite uncertainties about their safety and efficacy," explained Dr. Jihye Han, research specialist at Brigham and Women's Hospital and Harvard Medical School and lead author of the study.
Concerning Trends in Clinical Trial Design
Perhaps more concerning were the findings regarding the quality of evidence supporting these approvals. The researchers discovered that 50% of pivotal trials for first-in-class drugs (搜索) lacked clinical endpoints, instead relying on surrogate measures that may not directly correlate with patient outcomes. Additionally, 30% of these trials lacked proper blinding or comparator drugs—fundamental elements of rigorous clinical research.
"The degree of regulatory flexibility – particularly in terms of the methodological rigor of clinical trials supporting first-in-class drugs (搜索) – was striking," Han noted.
While the study didn't specifically examine trials submitted to the EMA, previous research indicates approximately 80% overlap in clinical trials submitted to both agencies, suggesting similar levels of clinical uncertainty may exist on both sides of the Atlantic.
Oncology Drugs Lead First-in-Class Approvals
Cancer (搜索) therapeutics represented the largest category of first-in-class approvals, accounting for 27% of drugs approved by both agencies between 2012 and 2022. Notably, about 90% of these oncology drugs were approved based on surrogate measures rather than definitive clinical outcomes.
"The urgency of treating life-threatening cancers has led to federal initiatives like the 21st Century Cures Act, which introduced the Real-Time Oncology Review program to speed up the approval process," Han explained. "There are also strong financial incentives for manufacturers to accelerate the approval process for oncology drugs, given their high price tags."
Balancing Innovation with Patient Safety
While regulatory flexibility can accelerate patient access to potentially groundbreaking treatments, it also introduces significant uncertainty about safety and effectiveness. The researchers emphasize that true clinical innovation should be measured by meaningful improvements in patient outcomes, not merely by novel mechanisms of action.
"A drug is clinically innovative only if it leads to meaningful improvements in patient outcomes, not just because it has the potential to do so," Han stated. "That's why it is critical to monitor real-world performance, especially when approval is based on surrogate endpoints and less rigorous trial designs. Regulatory flexibility should not come at the cost of patient safety and efficacy."
Post-Marketing Oversight Challenges
The study highlights particular concerns regarding the FDA's accelerated approval (搜索) pathway, which allows drugs to be approved based on surrogate measures with the expectation that post-market confirmatory trials will later verify actual clinical benefits.
"However, those surrogate measures have received increasing attention because many drugs approved through accelerated approval (搜索) have delayed or failed to confirm clinical benefits in post-marketing trials," Han cautioned.
The researchers also noted limitations in the FDA's ability to withdraw accelerated approval (搜索) drugs from the market, even when post-marketing trials fail to confirm effectiveness and safety.
Implications for Regulatory Policy
These findings come at a critical time when regulatory agencies worldwide are attempting to balance innovation with evidence standards. The researchers suggest that strengthening post-marketing oversight would be essential in shaping future regulatory landscapes to ensure the thoughtful introduction of first-in-class drugs (搜索).
"When a drug is approved based on limited clinical evidence, such as surrogate measures used under accelerated approval (搜索), clear post-marketing oversight is essential to confirm whether the drug is effective and safe as expected," Han concluded.
The study underscores the need for regulators to carefully balance incentives for innovation with rigorous, continuous assessment of evidence supporting new drug approvals—particularly for first-in-class therapies where clinical experience is limited and uncertainty is inherently higher.